Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

02/11/2013 | 10:44am US/Eastern
Recommend:
0
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
Recommend :
0
React to this article
Latest news on REGENERON PHARMACEUTICALS
3h agoDJBAYER : FDA Approves Bayer's Eylea for Diabetic Macular Edema Treatment
5h ago REGENERON PHARMACEUTICALS : Sets Date for Release of Q2 2014 Financial Results
7d ago REGENERON PHARMACEUTICALS : Two-Year Results From Phase 3 VIVID-DME Trial of EYL..
07/23 REGENERON PHARMACEUTICALS : Schedules Release of Q2 2014 Financial Results
07/18 REGENERON PHARMACEUTICALS : and Sanofi Report Dupilumab Study Results
07/18 REGENERON PHARMACEUTICALS : to Report Second Quarter 2014 Financial and Operatin..
07/18 REGENERON PHARMACEUTICALS : Two-Year Results From Phase 3 VIVID-DME Trial of EYL..
07/16 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Results from Phase 2b S..
07/14 REGENERON PHARMACEUTICALS : Assigned Patent
07/14 REGENERON PHARMACEUTICALS : and Sanofi Report Dupilumab Study Results
Advertisement
Chart
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
Regeneron Pharmaceuticals  : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF